Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung

JCO Precis Oncol. 2022 Jun:6:e2200009. doi: 10.1200/PO.22.00009.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Carcinoid Tumor* / drug therapy
  • Humans
  • Immunotherapy / adverse effects
  • Lung Neoplasms* / drug therapy
  • Temozolomide / therapeutic use

Substances

  • Temozolomide